Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
JJM van Dongen, VHJ van der Velden… - Blood, The Journal …, 2015 - ashpublications.org
Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 …
M Brüggemann, A Schrauder, T Raff, H Pfeifer… - Leukemia, 2010 - nature.com
Assessment of minimal residual disease (MRD) has acquired a prominent position in
European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the …
European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the …
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome–negative precursor B-lineage …
DA Thomas, S O'Brien, S Faderl… - Journal of Clinical …, 2010 - ascopubs.org
Purpose The adverse prognosis of CD20 expression in adults with de novo precursor B-
lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody …
lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody …
New markers for minimal residual disease detection in acute lymphoblastic leukemia
E Coustan-Smith, G Song, C Clark… - Blood, The Journal …, 2011 - ashpublications.org
To identify new markers for minimal residual disease (MRD) detection in acute
lymphoblastic leukemia (ALL), we compared genome-wide gene expression of …
lymphoblastic leukemia (ALL), we compared genome-wide gene expression of …
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances
I Della Starza, S Chiaretti, MS De Propris, L Elia… - Frontiers in …, 2019 - frontiersin.org
Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the
assessment of early response to therapy by minimal residual disease (MRD) monitoring has …
assessment of early response to therapy by minimal residual disease (MRD) monitoring has …
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow
G Basso, M Veltroni, MG Valsecchi… - Journal of clinical …, 2009 - ascopubs.org
Purpose Speed of blast clearance is an indicator of outcome in childhood acute
lymphoblastic leukemia (ALL). Availability of measurement of minimal residual disease …
lymphoblastic leukemia (ALL). Availability of measurement of minimal residual disease …
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
We have targeted CD22 as a novel tumor-associated Ag for recognition by human CTL
genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule …
genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule …
Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry
BL Wood - Cytometry Part B: Clinical Cytometry, 2016 - Wiley Online Library
Flow cytometry has become an indispensible tool for the diagnosis and classification of
hematopoietic neoplasms. The ability to rapidly distinguish cellular subpopulations via …
hematopoietic neoplasms. The ability to rapidly distinguish cellular subpopulations via …
Has MRD monitoring superseded other prognostic factors in adult ALL?
M Brüggemann, T Raff, M Kneba - Blood, The Journal of the …, 2012 - ashpublications.org
Significant improvements have been made in the treatment of acute lymphoblastic leukemia
(ALL) during the past 2 decades, and measurement of submicroscopic (minimal) levels of …
(ALL) during the past 2 decades, and measurement of submicroscopic (minimal) levels of …
Minimal residual disease in acute lymphoblastic leukemia: current practice and future directions
GP Contreras Yametti, TH Ostrow, S Jasinski, EA Raetz… - Cancers, 2021 - mdpi.com
Simple Summary Acute lymphoblastic leukemia minimal residual disease (MRD) refers to
the presence of residual leukemia cells following the achievement of complete remission …
the presence of residual leukemia cells following the achievement of complete remission …